%0 Journal Article
%A Chen, Li-Ju
%A Nguyen, Thi Ngoc Mai
%A Chang-Claude, Jenny
%A Hoffmeister, Michael
%A Brenner, Hermann
%A Schöttker, Ben
%T Association of polypharmacy with colorectal cancer survival among older patients.
%J The oncologist
%V 26
%N 12
%@ 1549-490X
%C Hoboken, NJ
%I Wiley
%M DKFZ-2021-01979
%P e2170-e2180
%D 2021
%Z #EA:C070#LA:C070#  /2021 Dec;26(12):e2170-e2180
%X In geriatric oncology, polypharmacy is often assessed during a comprehensive geriatric assessment. Previous studies about its association with survival among colorectal cancer (CRC) patients were inconclusive and had high risk for indication bias.A cohort study was conducted with 3,239 CRC patients, aged ≥65 years, who were recruited in Germany between 2003 and 2016 while being hospitalized for CRC surgery. We defined polypharmacy as concurrent use of 5 or more drugs, and excessive polypharmacy (EPP) as concurrent use of 8 or more drugs. Cox proportional hazards regression models were performed to assess the associations of polypharmacy with 5-year overall (OS), CRC specific (CSS), and non-cancer specific survival (NCS) with rigorous adjustment for morbidity to minimize indication bias (e.g., for cancer stage, functional status, and 13 common diseases/conditions).The prevalence of polypharmacy was 54.7
%K Colorectal cancer (Other)
%K Comprehensive Geriatric Assessment (CGA) (Other)
%K Geriatric Oncology (Other)
%K Polypharmacy (Other)
%K Survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34476870
%R 10.1002/onco.13961
%U https://inrepo02.dkfz.de/record/170520